Answer
Women of childbearing potential must continue effective contraception for at least 35 days after completing lorlatinib treatment, using a highly effective non-hormonal method because lorlatinib can make hormonal contraceptives ineffective, or adding a condom if hormonal contraception is unavoidable.
Sources for this answer
- Lorviqua 25 mg film coated tablets,Pfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 14Document updated
Sources checked